Actively Recruiting
Evaluating Anifrolumabs Impact on Blood Vessel Health and Vascular Risk Markers in Adults with Systemic Lupus Erythematosus
Led by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Updated on 2026-09-18
45
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether the drug anifrolumab can improve blood vessel function and reduce inflammation in people with systemic lupus erythematosus SLE, a condition that raises the risk of heart attacks and strokes due to blood vessel problems. This study focuses on patients aged 18 to 80 years with mild to moderate SLE and aims to assess changes in vascular function and inflammation compared to a placebo. Participants will receive intravenous infusions of either anifrolumab or a placebo every four weeks over an eight-month period, with a total of nine clinic visits. During some visits, special tests like the cardio-ankle vascular index CAVI to assess blood vessel function and FDG-PETCT scans to measure vascular inflammation will be performed. The study is double-blind, so neither participants nor researchers know who receives the drug or placebo. Throughout the trial, participants will undergo physical exams, blood and urine tests, heart function tests, chest X-rays, and symptom questionnaires. They will be monitored for changes in vascular markers, cardiovascular risk biomarkers, and safety through laboratory assessments and imaging. Each visit may take up to four hours, and participants are expected to comply with all study procedures for the full duration of approximately eight months.
CONDITIONS
Brief Title
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Research Team
L
Lubna K Hooda, R.N.
M
Mariana J Kaplan, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here